GenScript Has Developed Antibodies Specific for Influenza A Virus Detection
Mar 04, 2010
PISCATAWAY, N.J., Mar 4, 2010- Internationally recognized biology contract research organization, GenScript USA Inc. has recently launched Influenza A antibodies to help researchers detect and characterize influenza virus as part of globe effort in containing the spread of the virus.
GenScript’s polyclonal influenza A antibodies target specifically the following proteins in Western blot format:
HA (hemagglutinin) of influenza A (H1N1)
NA (neuraminidase) of influenza A (H1N1)
NS1 (non-structural protein 1) protein of influenza A (H1N1)
NS2 (non-structural protein 2) protein of influenza A (H1N1)
NP (nucleoprotein) protein of influenza A (H1N1)
PB1 (polymerase basic 1) protein of influenza A (H1N1)
PB2 (polymerase basic 2) protein of influenza A (H1N1)
PA (polymerase acidic) protein of influenza A (H1N1)
GenScript specializes in biological research and drug discovery services and products. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bio-reagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.
# # # #
For further information, please contact:
Executive Vice President
GENSCRIPT USA INC.
Your Innovation Partner in Drug Discovery!